<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03616899</url>
  </required_header>
  <id_info>
    <org_study_id>KPI-121-C-011</org_study_id>
    <nct_id>NCT03616899</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of KPI-121 in Subjects With DED</brief_title>
  <acronym>STRIDE 3</acronym>
  <official_title>A Phase 3, Double-masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle In Subjects With Dry Eye Disease (STRIDE 3)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kala Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kala Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to determine the efficacy and safety of KPI-121 0.25%&#xD;
      ophthalmic suspension compared to vehicle (placebo) in subjects who have a documented&#xD;
      clinical diagnosis of dry eye disease. The product will be studied over 14 days, with 1-2&#xD;
      drops instilled in each eye four times daily (QID).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 3, multi-center, double-masked, randomized, vehicle-controlled,&#xD;
      parallel-group study designed to evaluate the safety and efficacy of KPI-121 0.25% ophthalmic&#xD;
      suspension versus vehicle in subjects with dry eye disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 10, 2018</start_date>
  <completion_date type="Actual">February 5, 2020</completion_date>
  <primary_completion_date type="Actual">February 5, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline/Visit 2 (Day 1) in Ocular Discomfort Severity at Visit 4 (Day 15)</measure>
    <time_frame>Baseline/Visit 2 (Day 1) and to Visit 4 (Day 15)</time_frame>
    <description>Comparison of mean ocular discomfort severity between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using a 0-100 visual analog grading scale where 0 was better and 100 was worse.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline/Visit 2 (Day 1) Ocular Discomfort Severity at Visit 4 (Day 15) in the Subgroup of Participants With More Severe Ocular Discomfort</measure>
    <time_frame>Baseline/Visit 2 (Day 1) and to Visit 4 (Day 15)</time_frame>
    <description>Comparison of mean ocular discomfort severity between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using a 0-100 visual analog grading scale where 0 was better and 100 was worse, in a sub-group of participants with more severe ocular discomfort at baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline/Visit 2 (Day 1) in Bulbar Conjunctival Hyperemia at Visit 4 (Day 15)</measure>
    <time_frame>Baseline/Visit 2 (Day 1) and to Visit 4 (Day 15)</time_frame>
    <description>Comparison of mean bulbar conjunctival hyperemia between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using a 0-4 grading scale. The grading scale was based on the Cornea and Contact Lens Research Unit Grading Scale where 0 = none, 1 = very slight, 2 = slight, 3 = moderate and 4 = severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Conjunctival Hyperemia Scores at Visit 4 (Day 15) by Alternate Assessor</measure>
    <time_frame>Baseline/Visit 2 (Day 1) and to Visit 4 (Day 15)</time_frame>
    <description>Comparison of mean bulbar conjunctival hyperemia between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using a 0-4 grading scale. The grading scale was based on the Cornea and Contact Lens Research Unit Grading Scale where 0 = none, 1 = very slight, 2 = slight, 3 = moderate and 4 = severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline/Visit 2 (Day 1) in Ocular Discomfort Severity at Visit 3 (Day 8)</measure>
    <time_frame>Baseline/Visit 2 (Day 1) to Visit 3 (Day 8)</time_frame>
    <description>Comparison of mean ocular discomfort severity between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using a 0-100 visual analog grading scale where 0 was better and 100 was worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline/Visit 2 (Day 1) in Corneal Fluorescein Staining Score at Visit 4 (Day 15)</measure>
    <time_frame>Baseline/Visit 2 (Day 1) to Visit 4 (Day 15)</time_frame>
    <description>Comparison of mean corneal fluorescein staining between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using methods developed by the National Eye Institute (NEI) Dry Eye Workshop in evaluating 5 regions of the cornea (superior, inferior, nasal, temporal and central) using a 0-3 grading scale, where 0 = no visible staining, 1 = Mild, 2 = moderate and 3 = severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline/Visit 2 (Day 1) in Ocular Discomfort Severity at Visit 4 (Day 15) Using 7 Day Mean</measure>
    <time_frame>Baseline/Visit 2 (Day 1) to Visit 4 (Day 15)</time_frame>
    <description>Comparison of mean ocular discomfort severity between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using a 0-100 visual analog grading scale where 0 was better and 100 was worse.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">901</enrollment>
  <condition>Kerato Conjunctivitis Sicca</condition>
  <arm_group>
    <arm_group_label>KPI-121 0.25% Ophthalmic Suspension</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle of KPI-121 0.25% Ophthalmic Suspension</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KPI-121 Ophthalmic Suspension</intervention_name>
    <description>KPI-121 Ophthalmic Suspension</description>
    <arm_group_label>KPI-121 0.25% Ophthalmic Suspension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Vehicle for KPI-121 0.25% ophthalmic suspension</description>
    <arm_group_label>Vehicle of KPI-121 0.25% Ophthalmic Suspension</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have a documented clinical diagnosis of dry eye disease in both eyes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity or contraindication to the investigational product(s) or&#xD;
             components&#xD;
&#xD;
          -  History of glaucoma, IOP&gt;21 mmHg at the screening or randomization visits, or being&#xD;
             treated for glaucoma in either eye.&#xD;
&#xD;
          -  Diagnosis of: ongoing ocular infection; severe/serious ocular condition that in&#xD;
             judgment of Investigator could confound study assessments or limit compliance; or have&#xD;
             been exposed to an investigational drug within 30 days prior to screening.&#xD;
&#xD;
          -  In the opinion of the Investigator or study coordinator, be unwilling or unable to&#xD;
             comply with study protocol or unable to successfully instill eye drops.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Investigator #133</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #278</name>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <zip>36301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #146</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #148</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #280</name>
      <address>
        <city>Prescott</city>
        <state>Arizona</state>
        <zip>86301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #276</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85351</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #185</name>
      <address>
        <city>Azusa</city>
        <state>California</state>
        <zip>91702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #143</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92843</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #147</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #272</name>
      <address>
        <city>Hemet</city>
        <state>California</state>
        <zip>92545</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #155</name>
      <address>
        <city>Inglewood</city>
        <state>California</state>
        <zip>90301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #273</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #130</name>
      <address>
        <city>Mission Hills</city>
        <state>California</state>
        <zip>91345</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #247</name>
      <address>
        <city>Murrieta</city>
        <state>California</state>
        <zip>92562</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #215</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #111</name>
      <address>
        <city>Rancho Cordova</city>
        <state>California</state>
        <zip>95670</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #271</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #107</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #213</name>
      <address>
        <city>Westminster</city>
        <state>California</state>
        <zip>92683</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #218</name>
      <address>
        <city>Littleton</city>
        <state>Colorado</state>
        <zip>80120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #184</name>
      <address>
        <city>Brooksville</city>
        <state>Florida</state>
        <zip>34613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #262</name>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <zip>33484</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #279</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #265</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #157</name>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <zip>33773</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #189</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #136</name>
      <address>
        <city>Morrow</city>
        <state>Georgia</state>
        <zip>30260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #268</name>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <zip>30076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #266</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #187</name>
      <address>
        <city>Hoffman Estates</city>
        <state>Illinois</state>
        <zip>60169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #151</name>
      <address>
        <city>Lake Villa</city>
        <state>Illinois</state>
        <zip>60046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #128</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #250</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #125</name>
      <address>
        <city>New Albany</city>
        <state>Indiana</state>
        <zip>47150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #274</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40517</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #195</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #168</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #219</name>
      <address>
        <city>Winchester</city>
        <state>Massachusetts</state>
        <zip>01890</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #267</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #123</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #106</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #126</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #131</name>
      <address>
        <city>Washington</city>
        <state>Missouri</state>
        <zip>63090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #281</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #275</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #263</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89145</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #138</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89148</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #105</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #108</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #132</name>
      <address>
        <city>Wantagh</city>
        <state>New York</state>
        <zip>11793</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #264</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #217</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #149</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #102</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #163</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #282</name>
      <address>
        <city>Southern Pines</city>
        <state>North Carolina</state>
        <zip>28387</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #269</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #142</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #137</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #171</name>
      <address>
        <city>Mason</city>
        <state>Ohio</state>
        <zip>45040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #224</name>
      <address>
        <city>Cranberry Township</city>
        <state>Pennsylvania</state>
        <zip>16066</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #156</name>
      <address>
        <city>Kingston</city>
        <state>Pennsylvania</state>
        <zip>18704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #200</name>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <zip>17601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #277</name>
      <address>
        <city>West Mifflin</city>
        <state>Pennsylvania</state>
        <zip>15122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #240</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #127</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #270</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78681</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #188</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #174</name>
      <address>
        <city>Cedar Park</city>
        <state>Texas</state>
        <zip>78613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #140</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #124</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #259</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #175</name>
      <address>
        <city>Lakeway</city>
        <state>Texas</state>
        <zip>78734</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #182</name>
      <address>
        <city>League City</city>
        <state>Texas</state>
        <zip>77573</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #191</name>
      <address>
        <city>League City</city>
        <state>Texas</state>
        <zip>77573</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #177</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #258</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #186</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #176</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #222</name>
      <address>
        <city>Layton</city>
        <state>Utah</state>
        <zip>84041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator #119</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>July 31, 2018</study_first_submitted>
  <study_first_submitted_qc>August 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2018</study_first_posted>
  <results_first_submitted>February 9, 2021</results_first_submitted>
  <results_first_submitted_qc>March 9, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 2, 2021</results_first_posted>
  <last_update_submitted>March 9, 2021</last_update_submitted>
  <last_update_submitted_qc>March 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Keratoconjunctivitis</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 27, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/99/NCT03616899/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>901 subjects were randomized and all were included in the ITT population.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>KPI-121 0.25% Ophthalmic Suspension</title>
          <description>KPI-121 Ophthalmic Suspension: KPI-121 Ophthalmic Suspension</description>
        </group>
        <group group_id="P2">
          <title>Vehicle of KPI-121 0.25% Ophthalmic Suspension</title>
          <description>Vehicle: Vehicle for KPI-121 0.25% ophthalmic suspension</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="447"/>
                <participants group_id="P2" count="454"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="437"/>
                <participants group_id="P2" count="453"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>KPI-121 0.25% Ophthalmic Suspension</title>
          <description>KPI-121 Ophthalmic Suspension: KPI-121 Ophthalmic Suspension</description>
        </group>
        <group group_id="B2">
          <title>Vehicle of KPI-121 0.25% Ophthalmic Suspension</title>
          <description>Vehicle: Vehicle for KPI-121 0.25% ophthalmic suspension</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="447"/>
            <count group_id="B2" value="454"/>
            <count group_id="B3" value="901"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.6" spread="15.26"/>
                    <measurement group_id="B2" value="57.3" spread="15.53"/>
                    <measurement group_id="B3" value="57.4" spread="15.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="339"/>
                    <measurement group_id="B2" value="330"/>
                    <measurement group_id="B3" value="669"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="144"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="348"/>
                    <measurement group_id="B2" value="341"/>
                    <measurement group_id="B3" value="689"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="447"/>
                    <measurement group_id="B2" value="454"/>
                    <measurement group_id="B3" value="901"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline/Visit 2 (Day 1) in Ocular Discomfort Severity at Visit 4 (Day 15)</title>
        <description>Comparison of mean ocular discomfort severity between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using a 0-100 visual analog grading scale where 0 was better and 100 was worse.</description>
        <time_frame>Baseline/Visit 2 (Day 1) and to Visit 4 (Day 15)</time_frame>
        <population>Intent to Treat population minus subjects in each treatment group that discontinued the study by this time point or otherwise did not have this assessment completed</population>
        <group_list>
          <group group_id="O1">
            <title>KPI-121 0.25% Ophthalmic Suspension</title>
            <description>KPI-121 Ophthalmic Suspension: KPI-121 Ophthalmic Suspension</description>
          </group>
          <group group_id="O2">
            <title>Vehicle of KPI-121 0.25% Ophthalmic Suspension</title>
            <description>Vehicle: Vehicle for KPI-121 0.25% ophthalmic suspension</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline/Visit 2 (Day 1) in Ocular Discomfort Severity at Visit 4 (Day 15)</title>
          <description>Comparison of mean ocular discomfort severity between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using a 0-100 visual analog grading scale where 0 was better and 100 was worse.</description>
          <population>Intent to Treat population minus subjects in each treatment group that discontinued the study by this time point or otherwise did not have this assessment completed</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="434"/>
                <count group_id="O2" value="451"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.58" spread="19.379"/>
                    <measurement group_id="O2" value="-8.91" spread="17.579"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline/Visit 2 (Day 1) Ocular Discomfort Severity at Visit 4 (Day 15) in the Subgroup of Participants With More Severe Ocular Discomfort</title>
        <description>Comparison of mean ocular discomfort severity between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using a 0-100 visual analog grading scale where 0 was better and 100 was worse, in a sub-group of participants with more severe ocular discomfort at baseline.</description>
        <time_frame>Baseline/Visit 2 (Day 1) and to Visit 4 (Day 15)</time_frame>
        <population>Sub-group of Intent to Treat population with more severe ocular discomfort minus subjects in each treatment group that discontinued the study by this time point or otherwise did not have this assessment completed.</population>
        <group_list>
          <group group_id="O1">
            <title>KPI-121 0.25% Ophthalmic Suspension</title>
            <description>KPI-121 Ophthalmic Suspension: KPI-121 Ophthalmic Suspension</description>
          </group>
          <group group_id="O2">
            <title>Vehicle of KPI-121 0.25% Ophthalmic Suspension</title>
            <description>Vehicle: Vehicle for KPI-121 0.25% ophthalmic suspension</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline/Visit 2 (Day 1) Ocular Discomfort Severity at Visit 4 (Day 15) in the Subgroup of Participants With More Severe Ocular Discomfort</title>
          <description>Comparison of mean ocular discomfort severity between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using a 0-100 visual analog grading scale where 0 was better and 100 was worse, in a sub-group of participants with more severe ocular discomfort at baseline.</description>
          <population>Sub-group of Intent to Treat population with more severe ocular discomfort minus subjects in each treatment group that discontinued the study by this time point or otherwise did not have this assessment completed.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="296"/>
                <count group_id="O2" value="304"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.59" spread="20.373"/>
                    <measurement group_id="O2" value="-10.15" spread="18.739"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline/Visit 2 (Day 1) in Bulbar Conjunctival Hyperemia at Visit 4 (Day 15)</title>
        <description>Comparison of mean bulbar conjunctival hyperemia between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using a 0-4 grading scale. The grading scale was based on the Cornea and Contact Lens Research Unit Grading Scale where 0 = none, 1 = very slight, 2 = slight, 3 = moderate and 4 = severe.</description>
        <time_frame>Baseline/Visit 2 (Day 1) and to Visit 4 (Day 15)</time_frame>
        <population>Intent to Treat population minus subjects in each treatment group that discontinued the study by this time point or otherwise did not have this assessment completed</population>
        <group_list>
          <group group_id="O1">
            <title>KPI-121 0.25% Ophthalmic Suspension</title>
            <description>KPI-121 Ophthalmic Suspension: KPI-121 Ophthalmic Suspension</description>
          </group>
          <group group_id="O2">
            <title>Vehicle of KPI-121 0.25% Ophthalmic Suspension</title>
            <description>Vehicle: Vehicle for KPI-121 0.25% ophthalmic suspension</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline/Visit 2 (Day 1) in Bulbar Conjunctival Hyperemia at Visit 4 (Day 15)</title>
          <description>Comparison of mean bulbar conjunctival hyperemia between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using a 0-4 grading scale. The grading scale was based on the Cornea and Contact Lens Research Unit Grading Scale where 0 = none, 1 = very slight, 2 = slight, 3 = moderate and 4 = severe.</description>
          <population>Intent to Treat population minus subjects in each treatment group that discontinued the study by this time point or otherwise did not have this assessment completed</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="432"/>
                <count group_id="O2" value="449"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.35" spread="0.575"/>
                    <measurement group_id="O2" value="-0.18" spread="0.546"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Conjunctival Hyperemia Scores at Visit 4 (Day 15) by Alternate Assessor</title>
        <description>Comparison of mean bulbar conjunctival hyperemia between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using a 0-4 grading scale. The grading scale was based on the Cornea and Contact Lens Research Unit Grading Scale where 0 = none, 1 = very slight, 2 = slight, 3 = moderate and 4 = severe.</description>
        <time_frame>Baseline/Visit 2 (Day 1) and to Visit 4 (Day 15)</time_frame>
        <population>Intent to Treat population minus subjects in each treatment group that discontinued the study by this time point or otherwise did not have this assessment completed</population>
        <group_list>
          <group group_id="O1">
            <title>KPI-121 0.25% Ophthalmic Suspension</title>
            <description>KPI-121 Ophthalmic Suspension: KPI-121 Ophthalmic Suspension</description>
          </group>
          <group group_id="O2">
            <title>Vehicle of KPI-121 0.25% Ophthalmic Suspension</title>
            <description>Vehicle: Vehicle for KPI-121 0.25% ophthalmic suspension</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Conjunctival Hyperemia Scores at Visit 4 (Day 15) by Alternate Assessor</title>
          <description>Comparison of mean bulbar conjunctival hyperemia between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using a 0-4 grading scale. The grading scale was based on the Cornea and Contact Lens Research Unit Grading Scale where 0 = none, 1 = very slight, 2 = slight, 3 = moderate and 4 = severe.</description>
          <population>Intent to Treat population minus subjects in each treatment group that discontinued the study by this time point or otherwise did not have this assessment completed</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="437"/>
                <count group_id="O2" value="453"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.61" spread="0.646"/>
                    <measurement group_id="O2" value="-0.48" spread="0.657"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline/Visit 2 (Day 1) in Ocular Discomfort Severity at Visit 3 (Day 8)</title>
        <description>Comparison of mean ocular discomfort severity between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using a 0-100 visual analog grading scale where 0 was better and 100 was worse.</description>
        <time_frame>Baseline/Visit 2 (Day 1) to Visit 3 (Day 8)</time_frame>
        <population>Intent to Treat population minus subjects in each treatment group that discontinued the study by this time point or otherwise did not have this assessment completed.</population>
        <group_list>
          <group group_id="O1">
            <title>KPI-121 0.25% Ophthalmic Suspension</title>
            <description>KPI-121 Ophthalmic Suspension: KPI-121 Ophthalmic Suspension</description>
          </group>
          <group group_id="O2">
            <title>Vehicle of KPI-121 0.25% Ophthalmic Suspension</title>
            <description>Vehicle: Vehicle for KPI-121 0.25% ophthalmic suspension</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline/Visit 2 (Day 1) in Ocular Discomfort Severity at Visit 3 (Day 8)</title>
          <description>Comparison of mean ocular discomfort severity between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using a 0-100 visual analog grading scale where 0 was better and 100 was worse.</description>
          <population>Intent to Treat population minus subjects in each treatment group that discontinued the study by this time point or otherwise did not have this assessment completed.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="443"/>
                <count group_id="O2" value="453"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.05" spread="15.009"/>
                    <measurement group_id="O2" value="-5.83" spread="15.176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline/Visit 2 (Day 1) in Corneal Fluorescein Staining Score at Visit 4 (Day 15)</title>
        <description>Comparison of mean corneal fluorescein staining between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using methods developed by the National Eye Institute (NEI) Dry Eye Workshop in evaluating 5 regions of the cornea (superior, inferior, nasal, temporal and central) using a 0-3 grading scale, where 0 = no visible staining, 1 = Mild, 2 = moderate and 3 = severe.</description>
        <time_frame>Baseline/Visit 2 (Day 1) to Visit 4 (Day 15)</time_frame>
        <population>Intent to Treat population minus subjects in each treatment group that discontinued the study by this time point or otherwise did not have this assessment completed</population>
        <group_list>
          <group group_id="O1">
            <title>KPI-121 0.25% Ophthalmic Suspension</title>
            <description>KPI-121 Ophthalmic Suspension: KPI-121 Ophthalmic Suspension</description>
          </group>
          <group group_id="O2">
            <title>Vehicle of KPI-121 0.25% Ophthalmic Suspension</title>
            <description>Vehicle: Vehicle for KPI-121 0.25% ophthalmic suspension</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline/Visit 2 (Day 1) in Corneal Fluorescein Staining Score at Visit 4 (Day 15)</title>
          <description>Comparison of mean corneal fluorescein staining between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using methods developed by the National Eye Institute (NEI) Dry Eye Workshop in evaluating 5 regions of the cornea (superior, inferior, nasal, temporal and central) using a 0-3 grading scale, where 0 = no visible staining, 1 = Mild, 2 = moderate and 3 = severe.</description>
          <population>Intent to Treat population minus subjects in each treatment group that discontinued the study by this time point or otherwise did not have this assessment completed</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="437"/>
                <count group_id="O2" value="453"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.53" spread="0.800"/>
                    <measurement group_id="O2" value="-0.43" spread="0.739"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline/Visit 2 (Day 1) in Ocular Discomfort Severity at Visit 4 (Day 15) Using 7 Day Mean</title>
        <description>Comparison of mean ocular discomfort severity between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using a 0-100 visual analog grading scale where 0 was better and 100 was worse.</description>
        <time_frame>Baseline/Visit 2 (Day 1) to Visit 4 (Day 15)</time_frame>
        <population>Intent to Treat population minus subjects in each treatment group that discontinued the study by this time point or otherwise did not have this assessment completed.</population>
        <group_list>
          <group group_id="O1">
            <title>KPI-121 0.25% Ophthalmic Suspension</title>
            <description>KPI-121 Ophthalmic Suspension: KPI-121 Ophthalmic Suspension</description>
          </group>
          <group group_id="O2">
            <title>Vehicle of KPI-121 0.25% Ophthalmic Suspension</title>
            <description>Vehicle: Vehicle for KPI-121 0.25% ophthalmic suspension</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline/Visit 2 (Day 1) in Ocular Discomfort Severity at Visit 4 (Day 15) Using 7 Day Mean</title>
          <description>Comparison of mean ocular discomfort severity between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using a 0-100 visual analog grading scale where 0 was better and 100 was worse.</description>
          <population>Intent to Treat population minus subjects in each treatment group that discontinued the study by this time point or otherwise did not have this assessment completed.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="439"/>
                <count group_id="O2" value="452"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.76" spread="18.035"/>
                    <measurement group_id="O2" value="-7.91" spread="16.298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected at Visit 2 (Day 1) until they exited the study at Visit 4 (Day 15).</time_frame>
      <desc>Subjects reported in each treatment arm come from the safety population and represent different numbers of subjects than that reported for efficacy (the ITT population). Two subjects Two subjects were randomized to vehicle (and were included in the vehicle arm for efficacy analyses as part of the ITT population) but erroneously received KPI-121 (and are therefore included in the KPI-121 treatment arm for safety analyses).</desc>
      <group_list>
        <group group_id="E1">
          <title>KPI-121 0.25% Ophthalmic Suspension</title>
          <description>KPI-121 Ophthalmic Suspension: KPI-121 Ophthalmic Suspension</description>
        </group>
        <group group_id="E2">
          <title>Vehicle of KPI-121 0.25% Ophthalmic Suspension</title>
          <description>Vehicle: Vehicle for KPI-121 0.25% ophthalmic suspension</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrioventricular Block</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Eyelid injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Delusional disorder, unspecified type</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Schizoaffective disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="452"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="449"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="449"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="449"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Corneal infiltrates</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Foreign body sensation in eyes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>keratitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Ocular hypaeremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Scleral hyperaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Blepharospasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Conjunctival heamorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Conjunctival vascular disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Conjunctivitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Eye discharge</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Eyelid pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Eyelids pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Growth of eyelashes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Ocular discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Trichiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Vitreous floaters</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Instillation site pain</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="449"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Instillation site discharge</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Instillation site pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="449"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="449"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="449"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="449"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="452"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="452"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="449"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="452"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The agreement between the Principal Investigator and the Sponsor restricts the PI's rights to discuss or publish trial results until after the first to occur of the following:&#xD;
(a) publication of such multi-center clinical trial results; (b) notification by sponsor that such a multi-center clinical trial submission is no longer planned; or ( c) the eighteen ( 18) month anniversary of the completion, abandonment or termination of such multi-center clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>VP, Clinical Development</name_or_title>
      <organization>Kala Pharmaceuticals, Inc</organization>
      <phone>(781) 996-5252</phone>
      <email>Results011@kalarx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

